Advertisement
Screener

Mangoceuticals, Inc. (MGRX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

1.2 / 5 stars · 7/30 Roast Me

Mangoceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Mangoceuticals, Inc. (MGRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-19.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-05-19

  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Mangoceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2026-03-310.00%
10-Q · filed 2026-05-19
2025-12-310.00%
10-K · filed 2026-04-01
2025-09-300.00%
10-Q · filed 2025-11-14
2025-06-300.00%
10-Q/A · filed 2025-11-14
2025-03-310.00%
10-Q · filed 2025-05-15
2024-12-310.00%
10-K · filed 2025-03-20
2024-09-300.00%
10-Q · filed 2024-11-14
2024-06-300.00%
10-Q · filed 2024-08-14
2024-03-310.00%
10-Q · filed 2024-05-15
2023-12-310.00%
10-K · filed 2024-04-01
2023-09-300.00%
10-Q · filed 2023-10-27
2023-06-300.00%
10-Q · filed 2023-07-28
2023-03-310.00%
10-Q · filed 2023-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRYO CELL INTERNATIONAL INC (CCEL)United States$0.033B-11.02
BioRestorative Therapies, Inc. (BRTX)United States$0.064B
Park Dental Partners, Inc. (PARK)United States$0.094B
VIEMED HEALTHCARE, INC. (VMD)United States$0.336B29.92
agilon health, inc. (AGL)United States$1.272B-7.76
Progyny, Inc. (PGNY)United States$1.994B28.37
Sotera Health Co (SHC)United States$5.271B30.96
DAVITA INC. (DVA)United States$11.147B16.80